2004
Universal nevirapine upon presentation in labor to prevent mother-to-child HIV transmission in high prevalence settings
Stringer J, Sinkala M, Goldenberg RL, Kumwenda R, Acosta EP, Aldrovandi GM, Stout JP, Vermund SH. Universal nevirapine upon presentation in labor to prevent mother-to-child HIV transmission in high prevalence settings. AIDS 2004, 18: 939-943. PMID: 15060442, PMCID: PMC2745979, DOI: 10.1097/00002030-200404090-00012.Peer-Reviewed Original ResearchConceptsChild HIV transmissionUnknown HIV serostatusHIV serostatusHIV transmissionPreliminary efficacyLabour wardHIV DNA polymerase chain reactionSingle-dose nevirapinePrevention of motherProspective cohort studyEvidence of infectionHigh-prevalence settingsWeeks of lifeNevirapine administrationNevirapine coverageChild transmissionCohort studyComparison cohortAdherence ratesPrevalence settingsPolymerase chain reactionCord bloodDNA polymerase chain reactionHIVInfant specimens
2003
Timing of the maternal drug dose and risk of perinatal HIV transmission in the setting of intrapartum and neonatal single-dose nevirapine
Stringer J, Sinkala M, Chapman V, Acosta EP, Aldrovandi GM, Mudenda V, Stout JP, Goldenberg RL, Kumwenda R, Vermund SH. Timing of the maternal drug dose and risk of perinatal HIV transmission in the setting of intrapartum and neonatal single-dose nevirapine. AIDS 2003, 17: 1659-1665. PMID: 12853748, PMCID: PMC2745973, DOI: 10.1097/00002030-200307250-00010.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultBreast FeedingDrug Administration ScheduleFemaleHIV InfectionsHIV SeropositivityHumansInfant, NewbornInfectious Disease Transmission, VerticalLabor, ObstetricNevirapineObstetric Labor ComplicationsPregnancyPregnancy Complications, InfectiousProspective StudiesReverse Transcriptase InhibitorsRisk FactorsTime FactorsConceptsPerinatal HIV transmissionHIV transmissionInfant HIV infection statusNeonatal single-dose nevirapineMaternal drug doseSingle-dose nevirapineHIV infection statusProspective cohort studyPerinatal transmission rateOnset of laborMain outcome measuresMean drug concentrationWeeks of lifeRisk of transmissionNVP levelsNVP prophylaxisNVP syrupObstetrical clinicPerinatal transmissionCohort studyOral doseViral loadPregnant womenPolymerase chain reactionRisk factors